Stocktoria
Altimmune, Inc. ALT
Altimmune, Inc. (ALT) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $41,000 at a -214861.0% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.94 |
| Retained earnings / assets | -2.32 |
| EBIT / assets | -0.338 |
| Equity / liabilities | 4.086 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| ALT | Altimmune, Inc. | 4/9 | 0.63 | — | — |
| NTHI | NEONC TECHNOLOGIES HOLDINGS, INC. | 1/9 | — | — | — |
| AXIM | AXIM BIOTECHNOLOGIES, INC. | 3/9 | — | — | — |
| LYEL | Lyell Immunopharma, Inc. | 1/9 | -13.93 | — | — |
| IBO | IMPACT BIOMEDICAL INC. | 3/9 | -2.38 | — | — |
| TLPH | TALPHERA, INC. | 4/9 | — | — | — |
| HCWB | HCW Biologics Inc. | 2/9 | — | — | — |
About Altimmune, Inc.
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
FAQ
Is ALT financially healthy?
Altimmune, Inc.'s Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does ALT pay a dividend?
No, Altimmune, Inc. does not currently pay a dividend.
How profitable is ALT?
In FY2025, Altimmune, Inc. had a net margin of -214861.0% and a return on equity of -39.2%.
What is the analyst price target for ALT?
The average Wall-Street price target for Altimmune, Inc. is $15.45, about 427.3% above the recent price, from 10 analysts (consensus: buy).
Is ALT a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Altimmune, Inc.: a Piotroski F-score of 4/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.